Media coverage about Kala Pharmctls (NASDAQ:KALA) has trended somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kala Pharmctls earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.5850605786642 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Kala Pharmctls (NASDAQ:KALA) opened at 19.05 on Friday. Kala Pharmctls has a 52-week low of $10.43 and a 52-week high of $21.00. The company has a 50 day moving average price of $17.57 and a 200-day moving average price of $17.57. The firm’s market cap is $443.54 million.

In other Kala Pharmctls news, major shareholder Associates L.L.C. Cdk purchased 215,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were acquired at an average price of $15.00 per share, with a total value of $3,225,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Rajeev M. Shah purchased 533,333 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $7,999,995.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 1,282,666 shares of company stock worth $19,239,990.

TRADEMARK VIOLATION NOTICE: This report was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at

About Kala Pharmctls

Kala Pharmaceuticals Inc is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film.

Receive News & Ratings for Kala Pharmctls Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmctls and related companies with Analyst Ratings Network's FREE daily email newsletter.